Stocksigma LogoStocksigma Logo

Astonea Labs Reports Robust H1 FY27 Results and Outlines Multi-Year Revenue Targets

Astonea Labs reported strong H1 FY27 consolidated performance, with revenue rising 44.6% YoY to ₹95.86 crore, EBITDA surging 140.7% YoY to ₹13.20 crore

Astonea Labs Reports Robust H1 FY27 Results and Outlines Multi-Year Revenue Targets

Astonea Labs Ltd · Outcome · 14 Nov 2026, 9:27 pm

Astonea Labs Reports Robust H1 FY27 Results and Outlines Multi-Year Revenue Targets Astonea Labs reported strong H1 FY27 consolidated performance, with revenue rising 44.6% YoY to ₹95.86 crore, EBITDA surging 140.7% YoY to ₹13.20 crore (margin up 550 bps to 13.8%), and PAT jumping 153.3% YoY to ₹4.82 crore. Net working capital days improved to 107 days from 150 days YoY. The board approved acquiring a 51% stake in Longevity Science Pvt Ltd. Management guided for FY27 revenue exceeding ₹215 crore with 13–15% EBITDA margins, targeting ₹300 crore in FY28 and ₹405 crore in FY29.

Original exchange filing (PDF)

More announcements from Astonea Labs Ltd

All Astonea Labs Ltd announcements